Salud financiera de hoja de balance de Ligand Pharmaceuticals
Salud financiera controles de criterios 6/6
Ligand Pharmaceuticals tiene un patrimonio de accionistas total de $775.2M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $866.4M y $91.2M respectivamente. El BAIT de Ligand Pharmaceuticals es de $8.0M, por lo que su ratio de cobertura de intereses es de -1.1. Tiene efectivo e inversiones a corto plazo que ascienden a $226.9M.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | -1.1x |
| Efectivo | US$226.93m |
| Patrimonio | US$775.20m |
| Total pasivo | US$91.21m |
| Activos totales | US$866.41m |
Actualizaciones recientes sobre salud financiera
We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
May 29
These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease
Mar 17Recent updates
Ligand Pharmaceuticals: Solid Performer Performing Solidly
Jul 29Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected
Jul 18Should You Be Adding Ligand Pharmaceuticals (NASDAQ:LGND) To Your Watchlist Today?
Jun 29Subdued Growth No Barrier To Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) With Shares Advancing 27%
May 23Ligand: Buy This Pharma Royalty Aggregator To Generate Growth In Your Portfolio
Apr 30Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Not Flying Under The Radar
Dec 19Is Now The Time To Put Ligand Pharmaceuticals (NASDAQ:LGND) On Your Watchlist?
Jun 14We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
May 29Are Investors Undervaluing Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) By 45%?
May 07These 4 Measures Indicate That Ligand Pharmaceuticals (NASDAQ:LGND) Is Using Debt Reasonably Well
Jan 26We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Stay On Top Of Its Debt
Oct 21Ligand Pharmaceuticals: Struggling Along
Sep 25Growth Investors: Industry Analysts Just Upgraded Their Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Revenue Forecasts By 11%
Aug 11Here's Why Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt Responsibly
Jun 27Ligand Pharmaceuticals: Moving Parts Keep Moving
Mar 29We Think Ligand Pharmaceuticals (NASDAQ:LGND) Can Manage Its Debt With Ease
Mar 17Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($368.9M) de LGND superan a sus pasivos a corto plazo ($17.8M).
Pasivo a largo plazo: Los activos a corto plazo de LGND ($368.9M) superan a sus pasivos a largo plazo ($89.5M).
Historial y análisis de deuda-patrimonio
Nivel de deuda: LGND está libre de deudas.
Reducción de la deuda: LGND no tiene deuda en comparación con hace 5 años, cuando su ratio deuda-patrimonio era de 59.6%.
Cobertura de la deuda: LGND no tiene deuda, por lo tanto no necesita estar cubierta por flujo de caja operativo.
Cobertura de intereses: LGND no tiene deuda, por lo que la cobertura de pagos de intereses no es motivo de preocupación.